Publication Date
2020
Journal Title
Lung Cancer
Abstract
© 2020 Lee et al. Mutations in the epidermal growth factor receptor (EGFR) are common amongst those with non-small cell lung cancer and represent a major factor in treatment decisions, most notably in the advanced stages. Small molecule tyrosine kinase inhibitors (TKIs) that target the EGFR, such as erlotinib, gefitinib, icotinib, afatinib, dacomitinib and osimertinib, have all shown to be effective in this setting. Osimertinib, a third-generation EGFR TKI, is a favorable option, but almost all patients develop resistance at some time point. There are no effective treatment options for patients who progress on osimertinib, but ongoing trials will hopefully address this unmet need. The aim of this review is to provide a comprehensive review of the data with EGFR TKIs, management of the toxicities and the ongoing trials with this class of agents.
Volume Number
11
Pages
73 - 103
Document Type
Article
Status
Faculty
Facility
School of Medicine
Primary Department
Hematology/Medical Oncology
PMID
DOI
10.2147/LCTT.S258444